Total Valuation
Intellia Therapeutics has a market cap or net worth of CHF1.40B. The enterprise value is CHF1.89K.
Market CapCHF1.40B
Enterprise ValueCHF1.89K
Share Statistics
Intellia Therapeutics has 140,126,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding140,126,700
Owned by Insiders1.60%
Owned by Institutions34.28%
Financial Efficiency
Intellia Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -57.67%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-57.67%
Return on Capital Employed (ROCE)-0.60
Revenue Per Employee179.50K
Profits Per Employee-1.38M
Employee Count377
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Intellia Therapeutics is ―. Intellia Therapeutics’s PEG ratio is 0.09.
PE Ratio―
PS Ratio14.40
PB Ratio1.45
Price to Fair Value1.45
Price to FCF-2.75
Price to Operating Cash Flow-3.69
PEG Ratio0.09
Income Statement
In the last 12 months, Intellia Therapeutics had revenue of 67.67M and earned -412.69M in profits. Earnings per share was -3.81.
Revenue67.67M
Gross Profit51.75M
Operating Income-440.99M
Pretax Income-412.69M
Net Income-412.69M
EBITDA-396.77M
Earnings Per Share (EPS)-3.81
Cash Flow
In the last 12 months, operating cash flow was -463.99M and capital expenditures -2.12M, giving a free cash flow of -466.11M billion.
Operating Cash Flow-463.99M
Free Cash Flow-466.11M
Free Cash Flow per Share-3.33
Dividends & Yields
Intellia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta6.69
52-Week Price Change-11.27%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)95.00
Important Dates
Intellia Therapeutics upcoming earnings date is Nov 5, 2026, TBA (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Intellia Therapeutics as a current ratio of 5.08, with Debt / Equity ratio of 10.09%
Current Ratio5.08
Quick Ratio5.08
Debt to Market Cap0.07
Net Debt to EBITDA0.16
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Intellia Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Intellia Therapeutics EV to EBITDA ratio is -2.30, with an EV/FCF ratio of -2.57.
EV to Sales13.48
EV to EBITDA-2.30
EV to Free Cash Flow-2.57
EV to Operating Cash Flow-2.61
Balance Sheet
Intellia Therapeutics has CHF437.76M in cash and marketable securities with CHF73.41M in debt, giving a net cash position of CHF364.35M billion.
Cash & Marketable SecuritiesCHF437.76M
Total DebtCHF73.41M
Net CashCHF364.35M
Net Cash Per ShareCHF2.60
Tangible Book Value Per ShareCHF6.20
Margins
Gross margin is -46.48%, with operating margin of -651.67%, and net profit margin of -609.85%.
Gross Margin-46.48%
Operating Margin-651.67%
Pretax Margin-609.85%
Net Profit Margin-609.85%
EBITDA Margin-586.32%
EBIT Margin-609.85%
Analyst Forecast
The average price target for Intellia Therapeutics is CHF16.97, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF16.97
Price Target Upside87.49% Upside
Analyst ConsensusModerate Buy
Analyst Count12
Revenue Growth Forecast2.95%
EPS Growth Forecast34.62%